Use of antidepressant pharmacotherapy within the first year after diagnosis of diabetes mellitus: A study of a medicaid population
| Autor: | C M Kozma, W. Michael Dickson, David A. Sclar, Linda M. Robison, Tracy L. Skaer, C. Eugene Reeder |
|---|---|
| Rok vydání: | 1999 |
| Předmět: |
Pharmacology
medicine.medical_specialty education.field_of_study business.industry Incidence (epidemiology) Population Retrospective cohort study medicine.disease Pharmacotherapy Internal medicine Diabetes mellitus Cohort Medicine Pharmacology (medical) business Psychiatry education Depression (differential diagnoses) Glipizide medicine.drug |
| Zdroj: | Current Therapeutic Research. 60:415-422 |
| ISSN: | 0011-393X |
| DOI: | 10.1016/s0011-393x(99)80020-4 |
| Popis: | Structured diagnostic interviews indicate that the rate of depression among patients with diabetes mellitus (DM) is nearly 3 times that observed in the general population in the United States. Prevalence studies have reported a significant underdiagnosis of depression and a significant underutilization of antidepressant pharmacotherapy among patients with DM. The objective of this study was to determine the incidence of antidepressant utilization within the first year after diagnosis of type 1 (insulin-dependent) or type 2 (non-insulin-dependent) DM. This retrospective cohort study used adjudicated, patient-level, paid-claims data from the state of South Carolina's Medicaid program for the period January 1, 1990, through December 31, 1994. The study population comprised a statewide cohort of 3445 Medicaid beneficiaries diagnosed with type 1 or type 2 DM; aged 18 to 64 years; initiating pharmacotherapy with either insulin or a second-generation sulfonylurea (glipizide or glyburide); and without a prescription for antidepressant pharmacotherapy, insulin or an oral sulfonylurea (first- or second-generation) in the year before initiating a regimen to manage DM. Overall, 6.5% of patients (6.9% of patients with type 1 and 5.5% with type 2 DM) were prescribed antidepressant pharmacotherapy within the first year after beginning treatment with insulin or a second-generation sulfonylurea. Among patients with type 1 DM, 37.3% were prescribed a selective serotonin reuptake inhibitor compared with 50.9% of patients with type 2 DM. White patients were significantly more likely ( P |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|